Abstract
Background: LncRNAs perform a crucial impact on microglia’s activation in Parkinson’s disease (PD). Here, our purpose was to probe the function and involved mechanism of lncRNA SOX21-AS1 on microglial activation in PD. Methods: Mice were treated with MPTP, and BV2 cells were treated with LPS/ATP to build PD animal and cell models. Genes’ expression was measured using RT-qPCR, immunoblotting, and IHC stain. ELISA was applied for testing inflammatory factors’ levels. Cell viability and apoptosis were tested using kits. RIP and RNA pull-down assay were utilized for monitoring the bond of SOX21-AS1 to EZH2, and ChIP was applied for affirming the bond between EZH2 and SOCS3’s promoter. Results: The expression of SOX21-AS1 and SOCS3 was abnormal in PD cell and animal models. Inhibition of SOX21-AS1 repressed LPS/ATP-induced activation in BV2 cells and nerve damage caused by activated BV2 cells, alleviating the pathological features of PD mice. Further studies found that SOX21-AS1 epigenetically inhibited SOCS3 by recruiting EZH2 to SOCS3 promoter. SOX21-AS1 overexpression partially offset the repressive impact of SOCS3 enhancement on BV2 cell activation and the protective effect on nerve cells. Conclusion: SOX21-AS1 enhances LPS/ATP-induced activation of BV2 cells and nerve damage caused by activated BV2 cells though recruiting EZH2 to SOCS3’s promoter, thereby alleviating PD progression. Our research supplies new potential target for curing PD.
Journal Section:
Experimental Section: Research Article
References
1.
Poewe
W
, Seppi
K
, Tanner
CM
, Halliday
GM
, Brundin
P
, Volkmann
J
, et al. Parkinson disease
. Nat Rev Dis Primers
. 2017
;3
:17013
. 2.
Harms
AS
, Ferreira
SA
, Romero-Ramos
M
. Periphery and brain, innate and adaptive immunity in Parkinson’s disease
. Acta Neuropathol
. 2021
;141
(4
):527
–45
. 3.
Tansey
MG
, Wallings
RL
, Houser
MC
, Herrick
MK
, Keating
CE
, Joers
V
. Inflammation and immune dysfunction in Parkinson disease
. Nat Rev Immunol
. 2022
;22
(11
):657
–73
. 4.
Zeng
XS
, Geng
WS
, Jia
JJ
, Chen
L
, Zhang
PP
. Cellular and molecular basis of neurodegeneration in Parkinson disease
. Front Aging Neurosci
. 2018
;10
:109
. 5.
Johnson
ME
, Stecher
B
, Labrie
V
, Brundin
L
, Brundin
P
. Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis
. Trends Neurosci
. 2019
;42
(1
):4
–13
. 6.
Wang
T
, Shi
C
, Luo
H
, Zheng
H
, Fan
L
, Tang
M
, et al. Neuroinflammation in Parkinson’s disease: triggers, mechanisms, and immunotherapies
. Neuroscientist
. 2022
;28
(4
):364
–81
. 7.
Grimes
D
, Fitzpatrick
M
, Gordon
J
, Miyasaki
J
, Fon
EA
, Schlossmacher
M
, et al. Canadian guideline for Parkinson disease
. CMAJ (Can Med Assoc J)
. 2019
;191
(36
):E989
–1004
. 8.
Palmas
MF
, Ena
A
, Burgaletto
C
, Casu
MA
, Cantarella
G
, Carboni
E
, et al. Repurposing pomalidomide as a neuroprotective drug: efficacy in an alpha-synuclein-based model of Parkinson’s disease
. Neurotherapeutics
. 2022
;19
(1
):305
–24
. 9.
Rayaprolu
S
, Mullen
B
, Baker
M
, Lynch
T
, Finger
E
, Seeley
WW
, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease
. Mol Neurodegener
. 2013
;8
:19
. 10.
Fang
Y
, Jiang
Q
, Li
S
, Zhu
H
, Xu
R
, Song
N
, et al. Opposing functions of β-arrestin 1 and 2 in Parkinson’s disease via microglia inflammation and Nprl3
. Cell Death Differ
. 2021
;28
(6
):1822
–36
. 11.
Lee
SYH
, Yates
NJ
, Tye
SJ
. Inflammatory mechanisms in Parkinson’s disease: from pathogenesis to targeted therapies
. Neuroscientist
. 2022
;28
(5
):485
–506
. 12.
Zhang
QS
, Heng
Y
, Yuan
YH
, Chen
NH
. Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation
. Toxicol Lett
. 2017
;265
:30
–7
. 13.
Lawrence
G
, Holley
CL
, Schroder
K
. Parkinson’s disease: connecting mitochondria to inflammasomes
. Trends Immunol
. 2022
;43
(11
):877
–85
. 14.
Holoch
D
, Moazed
D
. RNA-mediated epigenetic regulation of gene expression
. Nat Rev Genet
. 2015
;16
(2
):71
–84
. 15.
Salta
E
, De Strooper
B
. Noncoding RNAs in neurodegeneration
. Nat Rev Neurosci
. 2017
;18
(10
):627
–40
. 16.
Yao
RW
, Wang
Y
, Chen
LL
. Cellular functions of long noncoding RNAs
. Nat Cell Biol
. 2019
;21
(5
):542
–51
. 17.
Statello
L
, Guo
CJ
, Chen
LL
, Huarte
M
. Author Correction: gene regulation by long non-coding RNAs and its biological functions
. Nat Rev Mol Cell Biol
. 2021
;22
(2
):159
. 18.
Honarmand Tamizkar
K
, Gorji
P
, Gholipour
M
, Hussen
BM
, Mazdeh
M
, Eslami
S
, et al. Parkinson’s disease is associated with dysregulation of circulatory levels of lncRNAs
. Front Immunol
. 2021
;12
:763323
. 19.
Zhang
H
, Yao
L
, Zheng
Z
, Koc
S
, Lu
G
. The role of non-coding RNAs in the pathogenesis of Parkinson’s disease: recent advancement
. Pharmaceuticals
. 2022
;15
(7
):811
. 20.
Zhang
L
, Fang
Y
, Cheng
X
, Lian
YJ
, Xu
HL
. Silencing of long noncoding RNA SOX21-AS1 relieves neuronal oxidative stress injury in mice with Alzheimer’s disease by upregulating FZD3/5 via the Wnt signaling pathway
. Mol Neurobiol
. 2019
;56
(5
):3522
–37
. 21.
Gu
F
, Ji
D
, Ni
H
, Chen
D
. SRY-box 21 antisense RNA 1 knockdown diminishes amyloid beta(25-35)-induced neuronal damage by miR-132/PI3K/AKT pathway
. Neurochem Res
. 2021
;46
(9
):2376
–86
. 22.
Xie
Y
, Zhang
S
, Lv
Z
, Long
T
, Luo
Y
, Li
Z
. SOX21-AS1 modulates neuronal injury of MMP(+)-treated SH-SY5Y cells via targeting miR-7-5p and inhibiting IRS2
. Neurosci Lett
. 2021
;746
:135602
. 23.
Qin
Y
, Qiu
J
, Wang
P
, Liu
J
, Zhao
Y
, Jiang
F
, et al. Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson’s disease
. Brain Behav Immun
. 2021
;91
:324
–38
. 24.
Weinberg
MS
, Samulski
RJ
, McCown
TJ
. Adeno-associated virus (AAV) gene therapy for neurological disease
. Neuropharmacology
. 2013
;69
:82
–8
. 25.
Chen
W
, Zheng
Q
, Huang
Q
, Ma
S
, Li
M
. Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease
. Elife
. 2022
;11
:11
. 26.
Liu
N
, Bai
L
, Lu
Z
, Gu
R
, Zhao
D
, Yan
F
, et al. TRPV4 contributes to ER stress and inflammation: implications for Parkinson’s disease
. J Neuroinflammation
. 2022
;19
(1
):26
. 27.
Cai
LJ
, Tu
L
, Huang
XM
, Huang
J
, Qiu
N
, Xie
GH
, et al. LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
. Mol Brain
. 2020
;13
(1
):130
. 28.
Wu
LH
, Lin
C
, Lin
HY
, Liu
YS
, Wu
CY
, Tsai
CF
, et al. Naringenin suppresses neuroinflammatory responses through inducing suppressor of cytokine signaling 3 expression
. Mol Neurobiol
. 2016
;53
(2
):1080
–91
. 29.
Wei
C
, Wang
H
, Xu
F
, Liu
Z
, Jiang
R
. LncRNA SOX21-AS1 is associated with progression of hepatocellular carcinoma and predicts prognosis through epigenetically silencing p21
. Biomed Pharmacother
. 2018
;104
:137
–44
. 30.
Schmidt
S
, Luecken
MD
, Trumbach
D
, Hembach
S
, Niedermeier
KM
, Wenck
N
, et al. Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease
. Nat Commun
. 2022
;13
(1
):4819
. 31.
Yang
X
, Zhang
Y
, Chen
Y
, He
X
, Qian
Y
, Xu
S
, et al. LncRNA HOXA-AS2 regulates microglial polarization via recruitment of PRC2 and epigenetic modification of PGC-1α expression
. J Neuroinflammation
. 2021
;18
(1
):197
. 32.
Manna
I
, Quattrone
A
, De Benedittis
S
, Iaccino
E
, Quattrone
A
. Roles of non-coding RNAs as novel diagnostic biomarkers in Parkinson’s disease
. J Parkinsons Dis
. 2021
;11
(4
):1475
–89
. 33.
Li
K
, Wang
Z
. lncRNA NEAT1: key player in neurodegenerative diseases
. Ageing Res Rev
. 2023
;86
:101878
. 34.
Kuo
MC
, Liu
SC
, Hsu
YF
, Wu
RM
. The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways
. J Biomed Sci
. 2021
;28
(1
):78
. 35.
Huang
T
, Zhao
JY
, Pan
RR
, Jiang
T
, Fu
XX
, Huang
Q
, et al. Dysregulation of circulatory levels of lncRNAs in Parkinson’s disease
. Mol Neurobiol
. 2023
;60
(1
):317
–28
. 36.
Boros
FA
, Vecsei
L
, Klivenyi
P
. NEAT1 on the field of Parkinson’s disease: offense, defense, or a player on the bench
. J Parkinsons Dis
. 2021
;11
(1
):123
–38
. 37.
Lin
D
, Zhang
H
, Zhang
J
, Huang
K
, Chen
Y
, Jing
X
, et al. α-Synuclein induces neuroinflammation injury through the il6st-AS/STAT3/HIF-1α Axis
. Int J Mol Sci
. 2023
;24
(2
):1436
. 38.
Lei
L
, Peng
G
, Luo
H
, Li
W
. SRY-box transcription factor 21 antisense divergent transcript 1: regulatory roles and clinical significance in neoplastic conditions and Alzheimer’s Disease
. J Cancer
. 2023
;14
(17
):3258
–74
. 39.
Xu
W
, Li
K
, Fan
Q
, Zong
B
, Han
L
. Knockdown of long non-coding RNA SOX21-AS1 attenuates amyloid-β-induced neuronal damage by sponging miR-107
. Biosci Rep
. 2020
;40
(3
). 40.
Chen
Y
, Li
Z
, Chen
X
, Zhang
S
. Long non-coding RNAs: from disease code to drug role
. Acta Pharm Sin B
. 2021
;11
(2
):340
–54
. 41.
Taghizadeh
E
, Gheibihayat
SM
, Taheri
F
, Afshani
SM
, Farahani
N
, Saberi
A
. LncRNAs as putative biomarkers and therapeutic targets for Parkinson’s disease
. Neurol Sci
. 2021
;42
(10
):4007
–15
. 42.
Qin
H
, Roberts
KL
, Niyongere
SA
, Cong
Y
, Elson
CO
, Benveniste
EN
. Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia
. J Immunol
. 2007
;179
(9
):5966
–76
. 43.
Rabie
MA
, Abd El Fattah
MA
, Nassar
NN
, Abdallah
DM
, El-Abhar
HS
. Correlation between angiotensin 1-7-mediated Mas receptor expression with motor improvement, activated STAT3/SOCS3 cascade, and suppressed HMGB-1/RAGE/NF-κB signaling in 6-hydroxydopamine hemiparkinsonian rats
. Biochem Pharmacol
. 2020
;171
:113681
. 44.
Park
KW
, Lin
CY
, Benveniste
EN
, Lee
YS
. Mitochondrial STAT3 is negatively regulated by SOCS3 and upregulated after spinal cord injury
. Exp Neurol
. 2016
;284
(Pt A
):98
–105
. 45.
Li
J
, Gao
W
, Zhao
Z
, Li
Y
, Yang
L
, Wei
W
, et al. Ginsenoside Rg1 reduced microglial activation and mitochondrial dysfunction to alleviate depression-like behaviour via the GAS5/EZH2/SOCS3/NRF2 Axis
. Mol Neurobiol
. 2022
;59
(5
):2855
–73
. 46.
Tsai
MC
, Chen
WJ
, Tsai
MS
, Ching
CH
, Chuang
JI
. Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats
. J Pineal Res
. 2011
;51
(2
):233
–45
. 47.
Yang
ZW
, Babitch
JA
. Detection and characterization of some new basic proteins in chicken postsynaptic densities
. J Neurochem
. 1986
;47
(1
):282
–90
. 48.
Song
H
, Chen
J
, Huang
J
, Sun
P
, Liu
Y
, Xu
L
, et al. Epigenetic modification in Parkinson’s disease
. Front Cell Dev Biol
. 2023
;11
:1123621
. 49.
Duan
R
, Du
W
, Guo
W
. EZH2: a novel target for cancer treatment
. J Hematol Oncol
. 2020
;13
(1
):104
. 50.
Mannino
D
, Scuderi
SA
, Casili
G
, Bova
V
, Cucinotta
L
, Lanza
M
, et al. Neuroprotective effects of GSK-343 in an in vivo model of MPTP-induced nigrostriatal degeneration
. J Neuroinflammation
. 2023
;20
(1
):155
. 51.
Sun
CC
, Zhu
W
, Li
SJ
, Hu
W
, Zhang
J
, Zhuo
Y
, et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway
. Genome Med
. 2020
;12
(1
):77
. 52.
Zhang
H
, Wang
SQ
, Wang
L
, Lin
H
, Zhu
JB
, Chen
R
, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression
. Cell Death Dis
. 2022
;13
(7
):657
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
